GlassScriptPhysician profile
Noelle E Reid
NPI 1043402985
$21,928.28
in general payments reported to CMS, 2019-2025
24 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $334 · 2020: $15K · 2021: $5,276 · 2022: $271 · 2023: $173 · 2024: $430 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $923.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $15,000.00 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $5,040.00 | 2021 | |
| Abbvie INC. | $476.79 | 2021-2025 | |
| Gilead Sciences, INC. | $351.44 | 2019-2025 | |
| Lilly USA, LLC | $150.80 | 2024-2025 | Mounjaro, Zepbound |
| Nevro Corp. | $123.28 | 2019 | |
| Allergan, INC. | $121.09 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $104.59 | 2022 | |
| Astellas Pharma US INC | $80.29 | 2024 | Veozah |
| Pfizer INC. | $66.18 | 2023-2025 | |
| Biohaven Pharmaceuticals, INC. | $56.26 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $54.48 | 2024-2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.16 | 2024 | Xifaxan |
| Genzyme Corporation | $34.86 | 2022 | |
| Novo Nordisk INC | $34.57 | 2025 | Wegovy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $28.89 | 2020 | |
| Glaxosmithkline, LLC. | $26.19 | 2022 | |
| Shire North American Group INC | $23.75 | 2019 | |
| Hologic Sales and Service, LLC | $22.14 | 2025 | Aptima, Thinprep 2000 Processor |
| Exact Sciences Corporation | $21.30 | 2025 | Cologuard Collection Kit |
| Ibsa Pharma INC. | $20.92 | 2025 | Licart, Tirosint, Flector |
| Supernus Pharmaceuticals, INC. | $18.19 | 2023 | Qelbree |
| Endo Pharmaceuticals INC. | $14.36 | 2021 | |
| Acella Pharmaceuticals, LLC | $13.75 | 2024 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Noelle Reid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.